David T Hagerty Selected Research

3- (2- (2- tert- butylphenylaminooxalyl)aminopropionylamino)- 4- oxo- 5- (2,3,5,6- tetrafluorophenoxy)pentanoic acid

1/2021	Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.
1/2020	Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension.
1/2020	A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.
1/2019	Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease.
1/2019	Emricasan (IDN-6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension.
1/2019	Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-Stage Liver Disease Scores Compared With Placebo.
9/2018	A Placebo-Controlled, Multicenter, Double-Blind, Phase 2 Randomized Trial of the Pan-Caspase Inhibitor Emricasan in Patients with Acutely Decompensated Cirrhosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David T Hagerty Research Topics

Disease

7	Inflammation (Inflammations) 01/2021 - 09/2018
7	Fibrosis (Cirrhosis) 01/2021 - 09/2018
3	Alcoholic Fatty Liver 01/2021 - 01/2019
3	Portal Hypertension 01/2021 - 01/2019
2	End Stage Liver Disease 01/2021 - 01/2019
2	Liver Diseases (Liver Disease) 01/2019 - 09/2018
2	Gout 10/2016 - 10/2016
2	Rheumatoid Arthritis 09/2005 - 11/2003
1	Hemorrhage 01/2021
1	Ascites 01/2021
1	Peritonitis 01/2021
1	Hepatic Encephalopathy 01/2021
1	Hepatorenal Syndrome 01/2021
1	Cicatrix (Scar) 01/2020
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2020
1	Chronic Hepatitis (Chronic Active Hepatitis) 01/2019
1	Hepatitis C 01/2019
1	Non-alcoholic Fatty Liver Disease 01/2019
1	Acute-On-Chronic Liver Failure 09/2018
1	Hyperuricemia 10/2016
1	Body Weight (Weight, Body) 11/2003

Drug/Important Bio-Agent (IBA)

7	CaspasesIBA 01/2021 - 09/2018
7	3- (2- (2- tert- butylphenylaminooxalyl)aminopropionylamino)- 4- oxo- 5- (2,3,5,6- tetrafluorophenoxy)pentanoic acidIBA 01/2021 - 09/2018
3	Biomarkers (Surrogate Marker)IBA 01/2020 - 01/2019
2	Pharmaceutical PreparationsIBA 01/2020 - 10/2016
2	lesinuradIBA 10/2016 - 10/2016
2	Uric Acid (Urate)IBA 10/2016 - 10/2016
1	Carbon Tetrachloride (Tetrachloromethane)IBA 01/2021
1	SodiumIBA 01/2021
1	DiureticsIBA 01/2021
1	Alanine Transaminase (SGPT)IBA 01/2020
1	EnzymesIBA 01/2020
1	BilirubinIBA 01/2019
1	Transaminases (Aminotransferases)IBA 01/2019
1	Caspase 3 (Caspase-3)IBA 01/2019
1	Keratin-18 (Keratin 18)IBA 01/2019
1	Probenecid (Benemid)FDA LinkGeneric 10/2016
1	BenzbromaroneIBA 10/2016
1	urate transporterIBA 10/2016
1	Abatacept (Orencia)FDA Link 09/2005
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2005
1	Antirheumatic Agents (DMARD)IBA 09/2005
1	Methotrexate (Mexate)FDA LinkGeneric 11/2003
1	AntigensIBA 11/2003
1	Proteins (Proteins, Gene)FDA Link 11/2003

Therapy/Procedure

3	Therapeutics 10/2016 - 11/2003